Trials / Withdrawn
WithdrawnNCT05487859
Acarbose in Combination With Standard Therapy in Metastatic Renal Cell Carcinoma (RCC)
A Pilot Study of the Immunomodulatory Agent Acarbose in Combination With Standard Therapy in Metastatic Renal Cell Carcinoma (RCC)
- Status
- Withdrawn
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 0 (actual)
- Sponsor
- University of Alabama at Birmingham · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to determine the safety and tolerability of acarbose in combination of immunotherapy based standard of care therapy in advanced renal cell carcinoma patients.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Acarbose Tablets | Acarbose Tablets PO ranging from 25 mg initially to 100 mg as tolerated |
Timeline
- Start date
- 2025-12-31
- Primary completion
- 2026-10-01
- Completion
- 2026-12-01
- First posted
- 2022-08-04
- Last updated
- 2026-02-17
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT05487859. Inclusion in this directory is not an endorsement.